Supportive care
The risk of<unk>  transmission to others and large contact investigations can be reduced if control measures are implemented immediately
For suspected patients
Mask the patient and isolate immediately in an airborne infection isolation room
All personnel entering the room should use respiratory protection at least as effective as an N95 respirator
If possible, allow only personnel with documentation of 2 doses of live<unk>  vaccine or laboratory evidence of immunity<unk>  IgG positive) to enter the room
Do not use the room for at least 2 hours after the patient leaves.
Mask the patient and isolate immediately in an airborne infection isolation room
All personnel entering the room should use respiratory protection at least as effective as an N95 respirator
If possible, allow only personnel with documentation of 2 doses of live<unk>  vaccine or laboratory evidence of immunity<unk>  IgG positive) to enter the room
Do not use the room for at least 2 hours after the patient leaves.
Immunocompetent:
MMR Vaccine (within 72 hours of exposure)
Immunocompromised, children <12 months, and others at high risk of complications:
IM Immune globulin (up to 6 days after exposure)
Consider checking with your local health authorities
MMR Vaccine (within 72 hours of exposure)
IM Immune globulin (up to 6 days after exposure)
Consider checking with your local health authorities
Measles
Atopic dermatitis
Smallpox
Bed bugs
Scabies
Contact dermatitis
Rat bite fever
Drug rash